Osman H, Murray M, Egan E, O'Dwyer M
Department of Haematology, University Hospital Galway, Newcastle Road, Galway.
Ir Med J. 2008 Nov-Dec;101(10):307-10.
We reviewed the reports of 79 newly diagnosed acute myeloid leukaemia patients admitted to our department between 1996 and 2005. Patients' characteristics and outcome were analysed. The acute myeloid leukaemia rate for all patients who received intensive chemotherapy, i.e. age > or = 60 years was 52.9%; in the age group (60-69) and > or = 70 years it was 62.5% and 44.4%, respectively. The acute myeloid leukaemia rate difference between the diagnosis periods (1996-2000) and (2001-2005) are statistically significant only in the age group (60-69) years (P = 0.018). For patients who received intensive chemotherapy and treatment other than intensive chemotherapy, the median overall survival was 9.73 and 3.6 months, respectively (P < 0.0001). There was no significant difference in overall survival between the age groups for the two diagnosis periods, except in patients aged > or = 80 years 3.0 and 0.63 month, respectively (P = 0.023). This study improved knowledge of characteristics and outcome of elderly acute myeloid leukaemia patients in our department.
我们回顾了1996年至2005年间收治于我科的79例新诊断急性髓系白血病患者的报告。分析了患者的特征及预后。所有接受强化化疗患者（即年龄≥60岁）的急性髓系白血病发生率为52.9%；在年龄组（60 - 69岁）及≥70岁患者中，该发生率分别为62.5%和44.4%。诊断时期（1996 - 2000年）与（2001 - 2005年）之间的急性髓系白血病发生率差异仅在年龄组（60 - 69岁）有统计学意义（P = 0.018）。接受强化化疗的患者与接受非强化化疗的患者相比，中位总生存期分别为9.73个月和3.6个月（P < 0.0001）。除≥80岁患者外，两个诊断时期各年龄组的总生存期无显著差异，≥80岁患者的总生存期分别为3.0个月和0.63个月（P = 0.023）。本研究增进了我们对我科老年急性髓系白血病患者特征及预后的了解。
